XML 249 R99.htm IDEA: XBRL DOCUMENT v3.25.2
Moderna Collaboration and License Agreement - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 42 Months Ended
Feb. 28, 2025
item
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
item
product
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
item
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2025
USD ($)
Moderna Collaboration and License Agreement                    
Collaboration revenues           $ 3,700 $ 12,600 $ 19,600 $ 14,900  
Collaboration revenues       $ 0 $ 9,197 3,729 $ 12,594 19,632 $ 14,919  
Option Right Collaboration Revenues                    
Moderna Collaboration and License Agreement                    
Collaboration revenues               3,800    
Collaboration and License Agreement | Research and Development Services                    
Moderna Collaboration and License Agreement                    
Noncurrent portion of deferred revenue       $ 41,300   41,300   41,300   $ 41,300
Moderna License Agreement | Research and Development Services                    
Moderna Collaboration and License Agreement                    
Collaboration revenues               38,700   42,400
Moderna License Agreement | Option Right Collaboration Revenues                    
Moderna Collaboration and License Agreement                    
Collaboration revenues                   $ 3,800
Moderna | Collaboration and License Agreement                    
Moderna Collaboration and License Agreement                    
Maximum of research targets | item     12              
Number of oncology research targets | item 12                  
Number of oncology research targets, nominated | item 10                  
Number of research targets, replacement nominations | item 4                  
Number of oncology research targets, ceased development | item 2                  
Number of nominated autoimmune target | item 2                  
Moderna | Collaboration and License Agreement | Research and Development Services                    
Moderna Collaboration and License Agreement                    
Upfront non-refundable payment received     $ 45,000     $ 45,000   $ 45,000    
Number of potential products to develop and commercialize | product     12              
Number of performance obligations | item           2        
Moderna | Collaboration and License Agreement | Research and Development Services | Minimum                    
Moderna Collaboration and License Agreement                    
Amount receivable per product     $ 247,000              
Moderna | Collaboration and License Agreement | Research and Development Services | Maximum                    
Moderna Collaboration and License Agreement                    
Amount receivable per product     $ 253,000              
Moderna | Moderna License Agreement                    
Moderna Collaboration and License Agreement                    
Collaboration revenues   $ 2,000